“…The first role is stimulation of signaling pathways, which contribute to malignant transformation, including proliferation in the absence of growth factors, protection from apoptosis in the absence of external survival factors and invasion (Kolibaba and Druker, 1997;Liu et al, 2000;Cross and Reiter, 2002;Arlinghaus and Sun, 2004). The second role of FTKs in hematological malignancies is the modulation of responses to DNA damage, rendering cells resistant to genotoxic therapies and causing genetic instability (Alimena et al, 1987;Kelman et al, 1989;Laneuville et al, 1992;Bedi et al, 1995;Nishii et al, 1996;Amarante-Mendes et al, 1998;Dubrez et al, 1998;Villamor et al, 1999;Honda et al, 2000;Salloukh and Laneuville, 2000;Sercan et al, 2000;Aoki et al, 2001;Greenland et al, 2001;Slupianek et al, 2001).…”